Sarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015)

Ziel:Offizielle Leitlinie, publiziert und koordiniert von der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG). Aufgrund ihrer Seltenheit und heterogenenHistopathologie stellen uterine Sarkome eine Herausforderung bzgl. des klinischen Managements dar und bedürfen von daher einem multidisziplinären Ansatz. Nach unserem Kenntnisstand existieren bis dato keine verbindlichen, evidenzbasierten Empfehlungen bzgl. des angemessenen Managements dieser heterogenen Tumore. Methoden: Die vorliegende S2k-Leitlinie ist das Ergebnis der Arbeit eines repräsentativen interdisziplinären Experten-Komitees, welches im Auftrag der Leitlinienkommission der DGGG eine systematische Literaturrecherche zum Thema Uterine Sarkome durchgeführt hat. Mitglieder der beteiligten Fachgesellschaften entwickelten in einem strukturierten Prozess einen formalen Konsensus. Empfehlungen: 1. Die Inzidenz und histopathologische Klassifikationen von uterinen Sarkomen. 2. Die klinische Symptomatik, Diagnostik und Stadieneinteilung von uterinen Sarkomen. 3. Das Management von Leiomyosarkome. 4. Das Management von endometrialen Stromasarkomen und undifferenzierten uterinen Sarkomen. 5. Das Management von Adenosarkomen als auch Karzinosarkomen. 6. Das Management von morcellierten uterinen Sarkomen Sarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015)

[1]  M. Beckmann,et al.  Surgical Methods for the Treatment of Uterine Fibroids - Risk of Uterine Sarcoma and Problems of Morcellation: Position Paper of the DGGG. , 2015, Geburtshilfe und Frauenheilkunde.

[2]  R. Simon,et al.  Incidental gynecologic neoplasms in morcellated uterine specimens: a case series with follow-up. , 2014, Human pathology.

[3]  T. Longacre,et al.  Endometrial Stromal Tumors: The New WHO Classification , 2014, Advances in anatomic pathology.

[4]  E. Oliva Cellular Mesenchymal Tumors of the Uterus: A Review Emphasizing Recent Observations , 2014, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[5]  J. Lang,et al.  Ovary and uterus-sparing procedures for low-grade endometrial stromal sarcoma: a retrospective study of 153 cases. , 2014, Gynecologic oncology.

[6]  A. Rosenberg WHO Classification of Soft Tissue and Bone, fourth edition: summary and commentary , 2013, Current opinion in oncology.

[7]  C. Haie-meder,et al.  Prognostic factors and outcome of undifferentiated endometrial sarcoma treated by multimodal therapy , 2013, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[8]  L. Giovanella,et al.  Diagnostic Performance of Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Imaging in Uterine Sarcomas: Systematic Review and Meta-Analysis of the Literature , 2013, International Journal of Gynecologic Cancer.

[9]  H. Mackay,et al.  Systematic chemotherapy for inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma: a systematic review. , 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).

[10]  E. Keung,et al.  External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma , 2013, Cancer.

[11]  J. Wathen,et al.  Adjuvant therapy for high‐grade, uterus‐limited leiomyosarcoma , 2013, Cancer.

[12]  E. Tanner,et al.  Management of uterine adenosarcomas with and without sarcomatous overgrowth. , 2013, Gynecologic oncology.

[13]  C. Haie-meder,et al.  A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  K. Godfrey,et al.  Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. , 2013, The Cochrane database of systematic reviews.

[15]  A. Secord,et al.  A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma. , 2012, Gynecologic oncology.

[16]  E. Tanner,et al.  High grade undifferentiated uterine sarcoma: surgery, treatment, and survival outcomes. , 2012, Gynecologic oncology.

[17]  J. Blay,et al.  Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial , 2012, The Lancet.

[18]  R. Abdah-bortnyak,et al.  Outcome and prognostic factors in endometrial stromal tumors: a Rare Cancer Network study. , 2012, International journal of radiation oncology, biology, physics.

[19]  P. Rose,et al.  Endometrial stromal sarcoma: analysis of recurrence following adjuvant treatment. , 2012, Gynecologic oncology.

[20]  R. Barakat,et al.  The role of cytoreductive surgery for newly diagnosed advanced-stage uterine carcinosarcoma. , 2011, Gynecologic oncology.

[21]  Sun-Kyung Park,et al.  The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma. , 2011, Gynecologic oncology.

[22]  T. Fehm,et al.  Pegylated liposomal doxorubicin and carboplatin in malignant mixed epithelial mesenchymal and mesenchymal gynecologic tumors: A phase II trial of the AGO study group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  R. Coleman,et al.  Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy. , 2011, Gynecologic oncology.

[24]  L. Horn,et al.  [Current TNM/FIGO classification for cervical and endometrial cancer as well as malignant mixed müllerian tumors. Facts and background]. , 2011, Der Pathologe.

[25]  Jubilee Brown,et al.  A Phase II Trial of Paclitaxel and Carboplatin in Women With Advanced or Recurrent Uterine Carcinosarcoma , 2010, International Journal of Gynecologic Cancer.

[26]  Jason D. Wright,et al.  Long-term outcome and natural history of uterine adenosarcomas. , 2010, Gynecologic oncology.

[27]  J. Palacios,et al.  Pathologic and molecular features of uterine carcinosarcomas. , 2010, Seminars in diagnostic pathology.

[28]  R. Mannel,et al.  Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  A. Munkarah,et al.  Ovarian and Uterine Carcinosarcomas: A Comparative Analysis of Prognostic Variables and Survival Outcomes , 2010, International Journal of Gynecologic Cancer.

[30]  E. Oliva,et al.  Endometrial Stromal Sarcomas: A Review of Potential Prognostic Factors , 2010, Advances in anatomic pathology.

[31]  T. Schultheiss,et al.  The role of adjuvant radiation in uterine sarcomas. , 2010, International journal of radiation oncology, biology, physics.

[32]  W. McCluggage,et al.  Mullerian Adenosarcoma of the Female Genital Tract , 2010, Advances in anatomic pathology.

[33]  Yong-Man Kim,et al.  The Role of Pelvic and/or Para-Aortic Lymphadenectomy in Surgical Management of Apparently Early Carcinosarcoma of Uterus , 2010, Annals of Surgical Oncology.

[34]  D. Timmerman,et al.  Clinical management of uterine sarcomas. , 2009, The Lancet. Oncology.

[35]  J. Coindre Grading of soft tissue sarcomas: review and update. , 2009, Archives of pathology & laboratory medicine.

[36]  J. Blay,et al.  Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  A. Black,et al.  Mullerian adenosarcoma of the cervix in a 10-year-old girl: case report and review of the literature. , 2009, Journal of pediatric and adolescent gynecology.

[38]  J. Tward,et al.  Does Radiotherapy or Lymphadenectomy Improve Survival in Endometrial Stromal Sarcoma? , 2009, International Journal of Gynecologic Cancer.

[39]  T. Dahhan,et al.  The efficacy of hormonal treatment for residual or recurrent low-grade endometrial stromal sarcoma. A retrospective study. , 2009, European journal of obstetrics, gynecology, and reproductive biology.

[40]  P. Sabbatini,et al.  Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study. , 2009, Gynecologic oncology.

[41]  J. Nesland,et al.  Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients , 2009, Histopathology.

[42]  E. Fridman,et al.  Uterine Leiomyosarcoma: Does the Primary Surgical Procedure Matter? , 2008, International Journal of Gynecologic Cancer.

[43]  R. Ali-Fehmi,et al.  Lymphadenectomy and Ovarian Preservation in Low-Grade Endometrial Stromal Sarcoma , 2008, Obstetrics and gynecology.

[44]  N. Mitra,et al.  Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. , 2008, Gynecologic oncology.

[45]  J. Chan,et al.  Endometrial stromal sarcoma: a population-based analysis , 2008, British Journal of Cancer.

[46]  V. Seshan,et al.  Uterine Carcinosarcomas and Grade 3 Endometrioid Cancers: Evidence for Distinct Tumor Behavior , 2008, Obstetrics and gynecology.

[47]  M. Franchi,et al.  Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). , 2008, European journal of cancer.

[48]  J. Chan,et al.  Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas , 2008, Cancer.

[49]  A. Gadducci,et al.  The management of patients with uterine sarcoma: a debated clinical challenge. , 2008, Critical reviews in oncology/hematology.

[50]  H. Kölbl,et al.  Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut). , 2007, Gynecologic oncology.

[51]  A. Wolfson,et al.  A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. , 2007, Gynecologic oncology.

[52]  P. Neven,et al.  Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcoma , 2007, British Journal of Cancer.

[53]  R. Barakat,et al.  Management of uterine malignancy found incidentally after supracervical hysterectomy or uterine morcellation for presumed benign disease , 2007, International Journal of Gynecologic Cancer.

[54]  R. Bristow,et al.  Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma. , 2007, Gynecologic oncology.

[55]  D. Mutch,et al.  A multi-institutional review of outcomes of endometrial stromal sarcoma. , 2007, Gynecologic oncology.

[56]  B. Monk,et al.  Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  T. Reimer,et al.  Concurrent Radiochemotherapy of Locally Recurrent or Advanced Sarcomas of the Uterus , 2006, Strahlentherapie und Onkologie.

[58]  B. Dörken,et al.  Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. , 2006, Gynecologic oncology.

[59]  S. Weiss,et al.  Grading of soft tissue sarcomas: the challenge of providing precise information in an imprecise world , 2006, Histopathology.

[60]  K. Dusenbery,et al.  Limitations of adjuvant radiotherapy for uterine sarcomas spread beyond the uterus. , 2004, Gynecologic oncology.

[61]  T. Fujisawa,et al.  Pulmonary metastases from uterine malignancies: results of surgical resection in 133 patients. , 2004, The Journal of thoracic and cardiovascular surgery.

[62]  M. Zhan,et al.  Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. , 2004, Gynecologic oncology.

[63]  J. Lucci,et al.  Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study. , 2004, Gynecologic oncology.

[64]  M. Takano,et al.  Malignant mixed Mullerian tumor of the uterine corpus with alpha-fetoprotein-producing hepatoid adenocarcinoma component. , 2003, Gynecologic oncology.

[65]  R. Barakat,et al.  Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus. , 2003, Gynecologic oncology.

[66]  G. Mor,et al.  Low-grade endometrial stromal sarcoma: hormonal aspects. , 2003, Gynecologic oncology.

[67]  M. Morgan,et al.  Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study. , 2003, Gynecologic oncology.

[68]  E. Venkatraman,et al.  Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma. , 2002, Gynecologic oncology.

[69]  G. Acs Intraoperative consultation in gynecologic pathology. , 2002, Seminars in diagnostic pathology.

[70]  E. Venkatraman,et al.  Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  W. McCluggage,et al.  Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas? , 2002, Journal of clinical pathology.

[72]  F. Amant,et al.  PTEN mutations in uterine sarcomas. , 2002, Gynecologic oncology.

[73]  L. Ramondetta,et al.  Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. , 2001, International journal of radiation oncology, biology, physics.

[74]  L. Schwartz,et al.  Endometrial stromal sarcoma: objective response to letrozole. , 2001, Gynecologic oncology.

[75]  F. Amant,et al.  Uterine Carcinosarcoma With Melanocytic Differentiation , 2001, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[76]  R. Pötter,et al.  Radiation therapy in the treatment of endometrial stromal sarcoma. , 2001, International journal of radiation oncology, biology, physics.

[77]  Q. Liao,et al.  [Clinical and pathological analysis on 106 cases with uterine sarcoma]. , 2001, Zhonghua fu chan ke za zhi.

[78]  G. Sutton,et al.  A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study. , 2000, Gynecologic oncology.

[79]  R. Mannel,et al.  Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study. , 2000, American journal of clinical oncology.

[80]  M. Weiser,et al.  Repeat resection of pulmonary metastases in patients with soft-tissue sarcoma. , 2000, Journal of the American College of Surgeons.

[81]  W. Frankel,et al.  Malignant mixed Müllerian tumor with rhabdoid features: a report of two cases and a review of the literature. , 1999, Gynecologic oncology.

[82]  P. Rose,et al.  Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study. , 1998, Gynecologic oncology.

[83]  T. Nicol,et al.  Complete hepatic resection of metastases from leiohyosarcoma prolongs survival , 1998, Journal of Gastrointestinal Surgery.

[84]  M. Fukunaga,et al.  Carcinosarcoma of the uterus with extensive neuroectodermal differentiation , 1996, Histopathology.

[85]  G. Sutton,et al.  Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. , 1996, Gynecologic oncology.

[86]  W. R. Hart,et al.  Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis. , 1995, The American journal of surgical pathology.

[87]  J. Berek,et al.  Uterine Sarcoma in Patients Operated on for Presumed Leiomyoma and Rapidly Growing Leiomyoma , 1994, Obstetrics and gynecology.

[88]  K. Chang,et al.  Primary Uterine Endometrial Stromal Neoplasms: A Clinicopathologic Study of 117 Cases , 1990, The American journal of surgical pathology.

[89]  P. Clement,et al.  Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases with a review of the literature. , 1990, Human pathology.

[90]  C. Wittekind,et al.  TNM Klassifikation maligner Tumoren , 1987 .

[91]  L. Blumenson,et al.  Uterine endolymphatic stromal myosis: a collaborative study. , 1984, Obstetrics and gynecology.

[92]  M. E. King,et al.  Myxoid leiomyosarcoma of the uterus: A report of six cases , 1982, The American journal of surgical pathology.

[93]  E. Wallach,et al.  Uterine leiomyomata: etiology, symptomatology, and management. , 1981, Fertility and sterility.

[94]  M. Baggish Mesenchymal tumors of the uterus. , 1974, Clinical obstetrics and gynecology.

[95]  T. Cunha,et al.  Uterine sarcomas: clinical presentation and MRI features. , 2015, Diagnostic and interventional radiology.

[96]  C. Fletcher,et al.  WHO classification of tumours of soft tissue and bone , 2013 .

[97]  M. Chorváth,et al.  [Uterine Sarcomas - a review]. , 2012, Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti.

[98]  P. Thall,et al.  Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  R. Kimmig,et al.  Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic tumors: a prospective phase I/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR). , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[100]  Peter Devilee,et al.  Pathology and Genetics of Tumours of the Breast and Female Genital Organs , 2003 .

[101]  F. Collin,et al.  Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[102]  E. Yordan,et al.  Phase II trial of etoposide in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. , 1996, Gynecologic oncology.

[103]  M. Shokeir,et al.  Malignant müllerian mixed tumor of the uterus with a prominent alpha-fetoprotein-producing component of yolk sac tumor. , 1996, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[104]  G. Sutton,et al.  Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. , 1992, American journal of obstetrics and gynecology.

[105]  J. Higier [Surgical treatment of uterine sarcoma]. , 1956, Ginekologia polska.